Jiang H H, Lin S
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing Neurosurgical Institute, Beijing 100070, China.
Zhonghua Wai Ke Za Zhi. 2020 Jan 1;58(1):70-74. doi: 10.3760/cma.j.issn.0529-5815.2020.01.015.
Glioblastoma (GBM) is the most common primary intracranial malignancy. The comprehensive treatment mode based on surgical resection has become the key to improve the prognosis of GBM and the quality of life of patients. This article reviews the progress of GBM in the fields of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy during the past twenty years, mainly explores the similarities and differences between the treatment strategies of newly diagnosed and recurrent GBM and analyzes the difficulties in the current clinical practice of GBM.
胶质母细胞瘤（GBM）是最常见的原发性颅内恶性肿瘤。基于手术切除的综合治疗模式已成为改善GBM患者预后和生活质量的关键。本文综述了过去二十年GBM在手术、放疗、化疗、靶向治疗和免疫治疗领域的进展，主要探讨初诊和复发GBM治疗策略的异同，并分析GBM当前临床实践中的难点。
